TDACU · Translational Development Acquisition Corp.
$11.48
At close · Oct 13
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“In connection with the Company's assessment of going concern considerations in accordance with ASC 205-40, "Presentation of Financial Statements-Going Concern," management has determined that the liquidity issues and mandatory liquidation and subsequent dissolution, should the Company be unable to complete a Business Combination by the end of the Completion Window, raise substantial doubt about the Company's ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after June 24, 2027. The Company's plan to deal with the uncertainty is to complete a Business Combination prior to June 24, 2027 and to receive working capital from its Sponsor. There is no assurance that the Company's plans to consummate a Business Combination or to receive working capital from the Sponsor will be successful.”View the 10-Q filed Aug 14, 2026
Market Cap
$208.73M
Shares
19.31M
Volume · Oct 13
101
Avg daily vol (7 sessions)
355
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$11.48
Open$11.48
Day$11.48–11.48
Available close range$10.71–17.29
Avg vol 30d2K
DataDec 2024–Oct 2026
Filing10-Q · Aug 14
The closing range uses available history since May 26, 2026; less than a full year is stored.
Up next
filed Aug 14, 2026
Technicals
trend & momentum for long-term holders illustrative — not investment adviceMarket signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Distributing
-9% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
No short-interest data
Volume signal
Normal
Volume near normal
Institution breadth
Steady
49 holders — mid 1-yr range
Price context
position in its available closing range
Range low $11
Now $11 · 12%
Range high $17
vs 50-day avg +2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Shell Companies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TDACU
this stock
Translational Development Acquisition Corp.
|
$208.73M | — | — | — | — |
|
VYLR
Vylor Inc.
|
$47.46B | — | — | — | — |
|
CLUS
Cluster Group Holdings Ltd Co
|
$8.00B | — | — | — | — |
|
DMII
Drugs Made In America Acquisition II Corp.
|
$649.10M | +2.9% | — | — | 0.2% |
|
EVAC
EQV Ventures Acquisition Corp. II
|
$603.77M | +3.0% | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
49
- % held
- 113.5%
- Net QoQ
- -2.9M sh
- Top holder
- Linden Advisors LP
Held
Float
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TDACU | -0.6% | +7.2% | +14.7% | -8.7% | +10.0% |
| SPY | -0.1% | +2.7% | +9.4% | +2.0% | +14.1% |
| vs SPY | -0.5% | +4.5% | +5.3% | -10.7% | -4.1% |